Safety signals of zolbetuximab in gastric or gastroesophageal junction adenocarcinoma: a comprehensive analysis of the FDA adverse event reporting system (FAERS) data - Top-Institutions - MDSpire

Safety signals of zolbetuximab in gastric or gastroesophageal junction adenocarcinoma: a comprehensive analysis of the FDA adverse event reporting system (FAERS) data

  • By

  • Li Lin

  • Maohua Chen

  • Chenmin Wu

  • Hong Chen

  • July 10, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Princess Margaret Cancer Centre
    Princess Margaret Cancer Centre

    Toronto, Ontario

    Key Differentiators

    • Oncology

  • #2

    Yonsei University College of Medicine
    Yonsei University College of Medicine

    Seoul, South Korea

    Key Differentiators

    • Oncology

  • #3

    Songdang Institute for Cancer Research
    Songdang Institute for Cancer Research

    Seoul, South Korea

    Key Differentiators

    • Oncology

  • #4

    our hospital
    our hospital

    Unknown, Unknown

    Key Differentiators

    • Oncology

Original Source(s)

Safety signals of zolbetuximab in gastric or gastroesophageal junction adenocarcinoma: a comprehensive analysis of the FDA adverse event reporting system (FAERS) data

  • by Li Lin, Maohua Chen, Chenmin Wu, Hong Chen

  • July 10, 2026

Related Content

Machine and deep learning based on magnetic resonance imaging to segment glioblastoma and predict the spread of recurrence: a multicenter retrospective protocol

Colorectal cancer liver metastases: mechanism and therapy

Inside the Rise of circRNA

Circio CEO Erik Wiklund reflects on the discovery of human circular RNA and its evolution into a fast-moving therapeutic modality

  • July 9, 2026

  • 12 min